6169 UK GAAP 2004. qxd 7 12 05 1:57 PM Page 12 Shire Pharmaceuticals Group plc Directors report The Directors present their report on the affairs of the Group and Mr Angus Russell Chief Financial Officer the Company together with the audited consolidated financial statements for the year ended 31 December 2004.
Dr Barry Price Senior Non-executive Director and Chairman of the Remuneration Committee Results and dividends The profit on ordinary activities before taxation of the Group for The Hon James Grant Non-executive Director the year ended 31 December 2004 was 57.4 million 2003: loss of 298.3 million.
The net assets of the Group as at 31 December Mr Ronald Nordmann Non-executive Director and 2004 were 2,232.2 million 2003: 2,308.5 million.
During the year Chairman of the Audit Committee until July 2004 ended 31 December 2004 the Directors resolved to pay an interim dividend of 1 penny per ordinary share for the six months ended Mr Robin Buchanan Non-executive Director 30 June 2004 2003: nil and on 1 March 2005 resolved to pay a second interim dividend of 2 pence per ordinary share for the six Mr David Kappler Appointed 5 April 2004 months ended 31 December 2004 2003: nil.
Non-executive Director and Chairman of the Audit Committee with effect from July 2004 Principal activity The principal activity of the Group is the research, development Dr Wilson Totten Stepped down 25 May 2004 and marketing of prescription medicines.
The Group focuses on Chief Scientific Officer three therapeutic areas: central nervous system, gastro-intestinal and general products.
Directors interests Details of the current Directors interests in the share capital of the Business review Company, as shown in the register maintained in accordance with A review of the Groups business and important events during the Section 325 of the Companies Act 1985, together with details year and likely future developments is set out in the Chairmans of the share options granted to them are disclosed in the Directors review on pages 2 and 3, the Chief Executives review on pages 4 remuneration report on pages 21 to 30. and 5 and the Financial review on pages 6 to 9.
Re-appointment Corporate governance Non-executive Directors are appointed for a term of two years, The Directors are committed to business integrity and subject to shareholder approval.
Re-appointment of non-executive professionalism and as an essential part of this commitment Directors following the expiry of such two-year period is subject the Board supports high standards of corporate governance.
to satisfactory performance and to Board approval.
Further Details concerning the Groups arrangements relating to corporate information concerning the Directors standing for re-election governance and its compliance with The Combined Code on at the Annual General Meeting, including their biographies, will Corporate Governance for the 2004 financial year are given be included in the Notice of Meeting to Shareholders.
on pages 14 to 18 and the remuneration policy contained in the Directors remuneration report is detailed on pages 21 to 30.
Interest in material contracts Other than the related party transactions disclosed below, none Authorised and called-up share capital of the current Directors had a material interest in any contract Details of the authorised and called-up share capital of the of significance to which the Company or any of its subsidiary Company as at 31 December 2004 and the changes during the undertakings was a party during the period under review.
year are set out in Note 25 to the consolidated financial statements.
Related party transactions Market purchases of ordinary shares The Company incurred professional fees with Stikeman Elliott, The Company was given authority at the 2004 Annual General a law firm in which The Hon James Grant is a partner, Meeting AGM to make market purchases of up to 47,985,315 of totaling $2.1 million for the year ended 31 December 2004 its own ordinary shares of 5p each at a maximum price per share 2003: $0.8 million.
of 105% of the middle market price.
The Company however did not purchase any shares during the year.
The authority will expire In April 2004 Shire BioChem Inc. BioChem, a subsidiary of Shire, at the 2005 AGM and approval will be sought from shareholders sold a Canadian property to NeuroChem Inc. for CAN$10.5 million.
at the 2005 AGM to renew the authority for a further year.
Dr Bellini, a non-executive Director of BioChem and, until 10 May 2003, a non-executive Director of Shire and Mr Nordmann, a nonResearch and development executive Director of Shire are both directors of NeuroChem Inc.
The Group continues an active research and development Dr Bellini had an indirect substantial interest in the issued share programme and as a result has incurred research and capital of NeuroChem Inc. at the time of the transaction.
development costs of 112.5 million in the financial year ended 31 December 2004 2003: 131.7 million.
These costs have In April 2004, Biochem contributed cash of CAN$5.0 million, been charged to the consolidated profit and loss account in equipment and intellectual property to the start-up of a new accordance with the Groups accounting policy.
Canadian-based pharmaceutical research and development organisation, ViroChem Pharma Inc. ViroChem, in return for Directors an equity interest and royalties on the sale of certain products The Directors who served during the year were as follows: subsequently launched by ViroChem.
BioChem has undertaken to invest an additional CAN$10.0 million in ViroChem in two Dr James Cavanaugh Chairman, Non-executive Director and equal tranches of CAN$5.0 million in April 2005 and April 2006.
Chairman of the Nomination Committee Dr Bellini, a non-executive Director of BioChem and, until 10 May 2003, a non-executive Director of Shire, had, at the time of the Mr Matthew Emmens Chief Executive Officer transaction, an indirect substantial interest in a company which is a co-investor in ViroChem.
12 6169 UK GAAP 2004. qxd 7 12 05 1:57 PM Page 13 Shire Pharmaceuticals Group plc Directors report Directors and Officers liability insurance Equal opportunities In the year under review, the Company and the Group maintained The Company operates an equal opportunities policy that aims an insurance policy for its Directors and Officers in respect of to treat individuals fairly and not to discriminate on the basis of liabilities arising out of any act, error or omission whilst acting in sex, race, ethnic origin or disability.
Applications for employment, their capacity as Directors or Officers.
including those by disabled persons, are fully considered on their merits, and employees are given appropriate training and Substantial shareholdings equal opportunities for career development and promotion.
The information disclosed to the Company pursuant to Sections 198 to 208 of the Companies Act 1985 regarding holdings in Disabled employees the ordinary share capital of the Company exceeding 3% as at Applications for employment by disabled persons are always 1 March 2005 shows: fully considered, bearing in mind the aptitudes of the applicant concerned.
In the event of members of staff becoming disabled, Franklin Resources, Inc. and its affiliates, managed on behalf every effort is made to ensure that their employment within the of its investment clients, have a holding of 12.58%: Group continues and that appropriate training is arranged.
It is the policy of the Group that the training, career development Fidelity International Limited has a holding of 5.87%: and promotion of disabled persons should, as far as possible, be identical to that of other employees and that reasonable Aviva plc has a holding of 3.92%: and accommodation is made wherever possible.
Legal & General Group has a holding of 3.22%.
Health, safety and welfare The Directors are committed to ensuring the health, safety and Political donations welfare of the Companys employees at work.
Accordingly, it is the The Company was given authority at the 2004 AGM to make EU Companys policy to manage its activities so as to avoid causing political donations as defined in Section 347A of the Companies any unnecessary or unacceptable risk to employees and those Act 1985 not exceeding 25,000 in total and to incur EU political who may be affected by the Companys business.
In addition, expenditure as defined in Section 347A of the Companies Act the Company takes its corporate social responsibilities seriously, 1985 not exceeding 25,000 in total.
The authorities were sought and maintains an active corporate social responsibility committee on a precautionary basis to avoid unwitting contravention of The as well as a global environmental health and safety team devoted Political Parties Elections and Referendums Act 2000.
The Group to promoting employee safety at and outside of work.
did not make any donations to EU political parties during the year ended 31 December 2004 2003: nil.
Payment of creditors It is the Companys policy to agree payment terms with its Charitable contributions suppliers, making sure the supplier is aware of those terms, and During the year, UK charitable contributions amounting to to abide by them.
The contributions were days outstanding were: primarily to charitable medical foundations.
For further 2004 2003 Number Number information, please refer to the Companys Corporate and Social Responsibility Report for 2004.
Group 18 12 Company 34 3 Employee involvement As at 31 December 2004, the Group employed 1,833 personnel, Annual General Meeting 337 of whom were based in the UK.
The Group places The Notice convening the Annual General Meeting to be held considerable value on the involvement of its employees and on 22 June 2005 can be found in a separate notice accompanying constantly seeks to develop employee involvement throughout the Annual Report.
To further this aim, the Company adopted an Employee Internal Communication Charter in 2004.
Pursuant Auditors to the Charter, employees are kept informed of strategy, current A resolution proposing the re-appointment of Deloitte & Touche business performance, product developments, changes in LLP as auditors to the Company will be put to the Annual General Company policy and processes, employee benefits including Meeting in accordance with Section 384 of the Companies Act pensions and health and safety arrangements.
The Audit Committee reviews both the level of the audit communicates with employees via regular internal publications fee and the level and nature of non-audit fees as part of its review Shire Dynamics and Shire Xpress, email, the Company intranet, of the adequacy and objectivity of the audit process.
regular all-employee meetings, functional and departmental meetings, through focus and consultation groups on specific By order of the Board topics, through employee surveys and via notice boards.
The Company also encourages involvement of employees in its performance through an annual individual objective setting process linked to corporate objectives, and through the operation of various employee share schemes, details of which are set out in the Directors remuneration report on pages 21 to 30 and Tatjana May in Note 25 to the consolidated financial statements.
Company Secretary 24 March 2005 The Companys employment polices are developed to reflect local legal, cultural and employment requirements and to maintain high standards wherever the Company operates.
Employees at all levels within the Company are encouraged to make the best possible contribution to the Companys overall success.
